Supreme Court rules unanimously on doctors’ challenge to abortion pill

By Around the Web


(Photo by Jakub Kriz on Unsplash)

By Katelynn Richardson
Daily Caller News Foundation

The Supreme Court sided unanimously Thursday against several doctors and pro-life medical associations who brought a challenge to the abortion pill.

In FDA v. Alliance for Hippocratic Medicine, the Supreme Court held that the doctors do not have standing to challenge the U.S. Food and Drug Administration’s (FDA) decision to roll back safety regulations for the abortion pill. While recognizing the plaintiffs have “sincere legal, moral, ideological, and policy objections to elective abortion and to FDA’s relaxed regulation of mifepristone,” Justice Brett Kavanaugh wrote in the majority rulings that those kind of objections are not enough to show the doctors would be injured by the FDA’s actions, noting the federal courts are “the wrong forum” for addressing their concerns.

“Under Article III of the Constitution, a plaintiff ’s desire to make a drug less available for others does not establish standing to sue,” Kavanaugh wrote. “Nor do the plaintiffs’ other standing theories suffice.”

Get the hottest, most important news stories on the Internet – delivered FREE to your inbox as soon as they break! Take just 30 seconds and sign up for WND’s Email News Alerts!

Those who object to the abortion pill and its manner of regulation “may always take their concerns to the Executive and Legislative Branches and seek greater regulatory or legislative restrictions on certain activities,” Kavanaugh wrote.

In August 2023, the Fifth Circuit Court of Appeals found that the FDA “failed to address several important concerns” when it loosened restrictions on the abortion drug mifepristone after 2016. The appeals court narrowed an injunction earlier issued by Trump-appointed U.S. District Court Judge Matthew Kacsmaryk, who required the FDA to reverse its initial 2000 approval of the pill altogether.

The FDA allowed distribution of mifepristone via mail and removed the initial in-person visit requirement in 2021. Earlier in 2016, it rolled back other safety regulations, enabling the drug to be used through ten weeks of pregnancy rather than seven.

The OB/GYNs and emergency room doctors who brought the challenge argued that women are more likely to require medical treatment as a result of the FDA’s relaxed safety standards, requiring them to sometimes, in violation of their conscience, complete an unfinished chemical abortion to address complications.

Content created by The Daily Caller News Foundation is available without charge to any eligible news publisher that can provide a large audience. For licensing opportunities of our original content, please contact [email protected].


Leave a Comment